--- title: "Sanofi Sits in Inhibrx's Top 5 as Phase 2 Lands: M&A Read" type: news slug: inhibrx-phase-2-ox40-keytruda-sanofi-strategic-holder-ma-read canonical_url: https://13finsight.com/news/inhibrx-phase-2-ox40-keytruda-sanofi-strategic-holder-ma-read published_at: 2026-05-12T15:09:01.288Z updated_at: 2026-05-12T15:09:03.736Z author: Alex Rivera author_title: Breaking News Editor author_url: https://13finsight.com/authors/alex-rivera word_count: 789 locale: en source: 13F Insight --- # Sanofi Sits in Inhibrx's Top 5 as Phase 2 Lands: M&A Read > Inhibrx Biosciences reported midphase results for INBRX-106 paired with Keytruda. The headline is the data. The story behind the data is the holder file — Sanofi's strategic stake, Perceptive and Viking's biotech-specialist sizing, and what the 13G ownership thresholds say about who is positioned for a take-out. Inhibrx Biosciences posted early Phase 2 readouts this week for INBRX-106 — an OX40 agonist — combined with Merck's Keytruda. Fierce Biotech framed the coverage with one extra word in the headline: "amid M&A buzz." That phrase is doing real work, and the explanation isn't in the slide deck. It's in the 13F file. Inhibrx is a 145-holder small-cap. That number is not noise — it is the entire institutional universe. Compare it to a Netflix-scale name with 3,789 holders or an eBay with 1,283. With 145, every line in the top 20 is doing meaningful work in the price. Eighteen of those top 20 are active discretionary positions; only two are passive index passes-through. That ratio inverts the usual large-cap dynamic, where index mandates dominate and active conviction sits five lines below the cut. The Strategic Holder That Doesn't Belong The line that matters most in Inhibrx's filing is the fourth one. Sanofi holds $77.8M of INBX. Sanofi is not a financial 13F filer in the sense of BlackRock or Fidelity — it is a global pharmaceutical operating company, and a sub-$100M U.S. equity position is not a treasury investment. It is a strategic stake, almost certainly tied to the prior commercial relationship between Sanofi and Inhibrx around eftansoma (Inhibrx's CD47 program, divested to Sanofi in 2024). A strategic stake by an operating pharma is not the same datapoint as a financial 13F position. Strategic holders sit on a cap table for two reasons: optionality on a future acquisition, or right-of-first-look on data. Either reason becomes more valuable, not less, when a Phase 2 trial reads out positively. The Specialist Spine The three largest financial holders look like a textbook small-cap biotech tape: HolderReported 13F Value13G % OwnedType Perceptive Advisors LLC$114.8M—Healthcare specialist fund Viking Global Investors LP$113.6M9.990%Tiger-lineage hedge fund Morgan Stanley$92.3M7.900%Broker / wealth management aggregate Sanofi$77.8M—Strategic pharma holder BlackRock, Inc.$61.4M5.300%Index complex Viking Global's 13G shows 9.990% beneficial ownership. That decimal is not coincidence — it is the deliberate ceiling. Crossing 10% triggers Section 16 reporting and short-swing profit recapture under SEC rules. A holder sitting at 9.99% is signaling that they want maximum upside without losing the ability to trade the position cleanly. Morgan Stanley's aggregated position at 7.9% reflects wealth-management and prime-brokerage flows; the conviction is in the Perceptive and Viking lines. Together the three financial specialists hold roughly $320M of a small-cap whose institutional universe runs 145 names deep. They are not going to exit on a midphase update — they are positioned for the next inflection. What the 13G Filings Tell You About Timing Inhibrx's 13D/G filing history (CUSIP 45720N103, accessible via the SEC's EDGAR full-text search) shows three recent activist-threshold filings: Viking Global — 9.990%, SCHEDULE 13G/A filed 2026-02-17. Down from 12.300% in a June 2024 13G, meaning Viking sold a slice into liquidity events but stayed deliberately under 10%. Morgan Stanley — 7.900%, SCHEDULE 13G filed 2026-02-11. BlackRock — 5.300%, SCHEDULE 13G filed 2026-01-21. All three are 13G filings — passive thresholds, not activist 13Ds. There is no investor publicly arguing for governance change or a forced sale. That is consistent with a small-cap where the catalysts are scientific (data) and corporate (M&A by a strategic), not operational. The M&A Pattern The combination of a strategic pharma sitting in the top 5, two healthcare specialists sized at material multiples of their typical small-cap entry, and a 9.99% holder who deliberately won't cross 10% is — historically — the pre-take-out pattern in small-cap biotech. It does not predict a bid. It tells you who is positioned to take one. Look for any of the following as confirmation: A Schedule 13D filing from a strategic — a 13G converted to 13D signals intent. A new sub-10% 13G from a different pharma operator entering the cap table. An 8-K disclosing material discussions, often triggered by a non-binding indication of interest. The next hard date is INBX's Q1 2026 earnings call (filing typically lands in mid-May). The next quarterly 13F window closes August 14, 2026, which is when any Q2 buying — including any new strategic stake — will become public. The Read The Phase 2 data is the news. The holder file is the trade. Eighteen of twenty top holders are active. Sanofi is in the top 5 as a strategic position. Viking sits at the 9.99% ceiling. Until any of those three facts shifts — Viking sells below 5%, Sanofi exits, or a competing strategic appears — INBX remains in the pre-event holder configuration that defines a take-out candidate. The data was the easy part. The cap table is the harder one. See the full INBX holder list, 13G filing history, and activity at /stocks/INBX. Track strategic-holder filings and activist signals at /filings/activists and /insights. ## FAQ ### Why does Sanofi own Inhibrx stock? Sanofi holds approximately $77.8M of INBX — a strategic stake tied to the prior commercial relationship between the two companies, including the 2024 divestiture of Inhibrx's CD47 program. Strategic operating-pharma stakes typically signal optionality on a future acquisition or right-of-first-look on clinical data, not a financial portfolio investment. ### What does Viking Global's 9.99% stake signal? Viking Global filed a SCHEDULE 13G/A on 2026-02-17 disclosing 9.990% beneficial ownership of INBX. The 9.99% figure is a deliberate ceiling — crossing 10% triggers Section 16 reporting and short-swing profit recapture. A holder sitting just below that threshold is positioned for maximum upside while preserving trading flexibility. ### Are Inhibrx's institutional holders active or passive? Of the 145 institutional holders tracked, 18 of the top 20 are active discretionary positions — including Perceptive Advisors ($114.8M), Viking Global ($113.6M), and Sanofi ($77.8M). Only BlackRock at $61.4M represents a meaningful passive index position. The ownership profile is heavily specialist. ### Are there any activist 13D filings on Inhibrx? No. The three most recent 13D/G filings on INBX (CUSIP 45720N103) are all passive 13G or 13G/A filings — from Viking Global, Morgan Stanley, and BlackRock. A 13G filing means the holder is not seeking control or governance change. There is no public activist campaign on the company. --- Source: 13F Insight — https://13finsight.com/news/inhibrx-phase-2-ox40-keytruda-sanofi-strategic-holder-ma-read Author: Alex Rivera — https://13finsight.com/authors/alex-rivera Last updated: 2026-05-12T15:09:03.736Z